Compare DCTH & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | CTKB |
|---|---|---|
| Founded | 1988 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.4M | 541.1M |
| IPO Year | 2015 | 2021 |
| Metric | DCTH | CTKB |
|---|---|---|
| Price | $16.94 | $4.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $22.00 | $5.63 |
| AVG Volume (30 Days) | 703.8K | ★ 819.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $193,015,000.00 |
| Revenue This Year | $24.54 | $5.42 |
| Revenue Next Year | $33.15 | $7.03 |
| P/E Ratio | $418.75 | ★ N/A |
| Revenue Growth | N/A | ★ 17.67 |
| 52 Week Low | $8.12 | $3.28 |
| 52 Week High | $17.42 | $6.18 |
| Indicator | DCTH | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 46.91 |
| Support Level | $10.16 | $4.15 |
| Resistance Level | $17.42 | $4.73 |
| Average True Range (ATR) | 0.77 | 0.25 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 82.60 | 46.20 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.